Nycomed Gmbh

Takeda Gmbh

Altana Pharma Ag

4sc Ag

Beate Schmidt

Geert Jan Sterk

Hans-Peter Kley

Armin Hatzelmann

Degenhard Marx

Dieter Flockerzi

Gerhard Grundler

Hermann Tenor

Christof Zitt

Steffen Weinbrenner

Josef Stadlwieser

Anke Heuser

Ulrich Kautz

Torsten Dunkern

Heiko Bernsmann

Rolf-Peter Hummel

Andreas Pahl

Christian Scheufler

Martin Feth

Andrea Wohlsen

Wiro M P B Menge

Raimund Külzer

Raimund Kuelzer

Alexander Sudau

Martin Viertelhaus

Guido Hanauer

Thomas Maier

Thomas Beckers

Klaus Eistetter

Astrid Zimmermann

Volker Gekeler

Petra Gimmnich

Mathias Schmidt

Ernst Sturm

Deborah Ockert

Johannes A M Christiaans

Ewald Benediktus

Ragna Hussong

Wilhelm Wurst

Clemens Braun

Juergen Volz

Daniela Hauser

Olaf Nimz

Matthias Mueller

Imre Schlemminger

Alexander Weber

Jürgen Volz

Thomas Stengel

Florian Dehmel

Dirk Bredenbröker

Jörg Kemkowski

Jörg Diefenbach

Dirk Bredenbroeker

Joerg Kemkowski

Stefan Kaupp

Martin P Feth

Maria Vittoria Chiesa

Matthias MÜLLER

Johannes Barsig

Wiro MPB Menge

Raimund c/o Nycomed Gmbh Külzer

The invention relates to a novel process for preparing crystalline ciclesonide with an advantageous particle size and to the use for producing pharmaceutical preparations, in particular for topical use. The crystalline ciclesonide obtained by the novel process has advantageous aerodynamic properties, and can be further processed to inhalable or nasally administered pharmaceutical preparations without further mechanical micronization.

Process for preparing crystalline ciclesonide with defined particle size

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.

Methylpyrrolopyrimidinecarboxamides

The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Pyrazolone-derivatives and their use as PDE-4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Pyrazolone derivatives as PDE4 inhibitors

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

The compounds of Formula (I), wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Methylpyrrolopyridinecarboxamides

The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.

Roflumilast for the treatment of diabetes mellitus type 2

The compounds of Formula (I), in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines

The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.

The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1. 

Thiophene-imidazopyridines

The compounds of formula I in which R1, R2, R3, R31, R4, R5, R6 and R7 have the meanings as indicated in the description, are novel effective PDE4 inhibitors.

3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors

The compounds of formula (I) in which R1, R2 and R3 have the meanings as given in the description are novel effective PDE2 inhibitors.

Triazolophthalazines

The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus.

Roflumilast for the treatment of diabetes mellitus

Growing community of inventors

Allensbach, Germany

Beate Schmidt